Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02030483 · ClinicalTrials.gov registry record · Phase 1
Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02030483: Clinical Trial Phase 1 study, sponsored by Weill Medical College of Cornell University.
NCT02030483 is a Phase 1 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02030483, a Phase 1 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Our hypothesis is that treating relapsed or refractory multiple myeloma with PD 0332991 (Palbociclib) in combination with lenalidomide will result will be both effectively inducing myeloma plasma cell death as well maintaining a favorable side effect profile.
Primary Outcome
The primary endpoint of objective determination of the maximum tolerated dose will be assessed through safety reports. The frequency of subjects experiencing toxicities will be tabulated. Toxicities will be assessed and graded according to CTCAE v. 4.0 terminology
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Palbociclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Why NCT02030483 stopped before completion
NCT02030483 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02030483 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02030483 about?
NCT02030483 is a clinical study titled "Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma". Our hypothesis is that treating relapsed or refractory multiple myeloma with PD 0332991 (Palbociclib) in combination with lenalidomide will result will be both effectively inducing myeloma plasma cell death as well maintaining a favorable side effect profile.
What is the current status of trial NCT02030483?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2014-02. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02030483?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Palbociclib (DRUG).
Who is sponsoring clinical trial NCT02030483?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02030483's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia